CAN CELLULAR FIBRONECTIN INHIBIT METASTATIC IMPLANTATION?

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13704
Amount: $49,996.00
Phase: Phase I
Program: SBIR
Awards Year: 1990
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Fibrogenex Inc
7701 W Arcadia, Morton Grove, IL, 60053
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Clyde R Goodheart
 (708) 965-7114
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE LONG-TERM OBJECTIVE OF THE RESEARCH IS TO DETERMINE THE EFFICACY OF CELLULAR FIBRONECTIN IN PREVENTING THE IMPLANTATION OF METASTATIC TUMOR CELLS AT SURGICAL INCISIONS. PHASE I FEASIBILITY STUDIES WILL BE CONDUCTED INMICE, USING A MODEL FOR METASTATIC IMPLANTS DEVELOPED AT EVANSTON HOSPITAL. SUFFICIENT CELLULAR FIBRONECTIN WILL BE PRODUCED AND PURIFIED FROM SYNGENEIC MICE TO PERMIT THREE EXPERIMENTS: (1) TO DETERMINE THE EFFECT OF CONCENTRATION OF BIRONECTIN APPLIED TO THE WOUND TO THE FREQUENCY OF TUMOR FORMATION AT THE SITE OF TRAUMA, (2) TO DETERMINE THE EFFECT OF ENHANCEMENT OF WOUND HEALING BY CELLULAR FIBRONECTIN ON THE DEVELOPMENT OF METASTATIC IMPLANTS, AND (3) TO DETERMINE WHETHER CELLULAR FIBRONECTIN APPLIED AT VARIOUS CONCENTRATIONS TO THE CELLS PRIOR TO INOCULATION HAS AN EFFECT ON THE TENDENCY OF TA3HA TUMOR CELLS TO IMPLANT AT WOUND SITES IN STRAIN A MICE. PHASE II STUDIES WILL EXTEND THE PROGRAM TO PRODUCTION OF SUFFICIENT HUMAN CELLULAR FIBRONECTIN FOR TOXICITY STUDIES AND PRIMARY HUMAN CLINICAL STUDIES FOR SURFACE WOUND HEALING AND POSSIBLE APPLICATION IN TUMOR SURGERY.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government